Key result
Early IV milrinone enters pilot testing for safety and feasibility in aneurysmal subarachnoid hemorrhage.
Why the study?
The safety, feasibility, and standardized clinical protocol for early intravenous milrinone therapy for delayed cerebral ischemia and vasospasm after aneurysmal subarachnoid hemorrhage needed evaluation.
Does early intravenous milrinone therapy improve safety and feasibility in patients with delayed cerebral ischemia and vasospasm after aneurysmal subarachnoid hemorrhage?
Does early intravenous milrinone therapy improve safety and feasibility in patients with delayed cerebral ischemia and vasospasm after aneurysmal subarachnoid hemorrhage?
This pilot study aims to evaluate the safety and feasibility of early IV milrinone for delayed cerebral ischemia and vasospasm after aneurysmal subarachnoid hemorrhage.
May support standardized milrinone protocols for aSAH DCI; leaves open efficacy confirmation in randomized trials.
To evaluate the safety and feasibility of early intravenous (IV) milrinone therapy for delayed cerebral ischemia (DCI) and vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) and to develop a standardized clinical protocol for its implementation in neurocritical care practice.
No takes yet. Share an insight, caveat, or question.
Gutzwiller et al. (2026) studied this question. Early intravenous milrinone therapy for delayed cerebral ischemia and vasospasm after aneurysmal subarachnoid hemorrhage is being evaluated for safety and feasibility in a pilot study.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: